A Phase IIa trial to evaluate MRG-201 in subjects with a predisposition for keloid formation.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs MRG 201 (Primary)
- Indications Fibrosis
- Focus Therapeutic Use
- 08 Nov 2017 According to a miRagen Therapeutics media release, this trial is expected to commence in the first half of 2018 and trial data is anticipated in 2019.
- 17 Aug 2017 New trial record
- 11 Aug 2017 According to a miRagen Therapeutics media release, company plans to initiate this trial in 2018.